ClinicalTrials.gg
Active, not recruitingNCT07030504Updated Jun 22, 2025

To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects

A Phase 1 interventional study of SAL0133 and SAL0133 placebo in Pharmacokinetics, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 2 years 5 months after the study started (first participant enrolled Jan 2023, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the safety and tolerance of single and multiple administrations of SAL0133 tablets in adult healthy subjects in China receptivity.

Read the detailed description

This study was divided into two parts: Part A and Part B. Part A was single-center, randomized, double-blind, and placebo control, single-dose escalation study (SAD) was conducted to evaluate the safety, tolerability and pharmacokinetic characteristics of SAL0133 tablets after a single dose. Furthermore, food effect would be preliminarily evaluated the influence of the pharmacokinetic characteristics of SAL0133 tablets in Part A. Part B was a single-center, randomized, double-blind, placebo controlled, multiple-dose escalation study was conducted to evaluate the safety, tolerability and pharmacokinetic characteristics of SAL0133 tablets after multiple doses.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd. is the lead sponsor of 42 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants have fully understood the trial's objectives, procedures, and potential adverse effects, and voluntarily signed form prior to the trial.
  • Healthy male or female adults aged 18 to 65 years (inclusive).The gender ratio shall be no less than one third.
  • Body weight ≥50 kg for male participants and ≥45 kg for female participants at screening, with a (BMI) between 19.0 and 26.0 kg/m2 (inclusive; BMI = body weight ÷ height2).
  • No abnormalities or only slight abnormalities not of tests/examinations (including physical examination, vital sign examination, blood routine, urine routine, blood biochemistry, coagulation function, five thyroid function tests, five pituitary function tests, serological virology, 12-lead , normal chest position, abdominal B-ultrasound, etc) as judged by the investigator.
  • The subject or their partner had no pregnancy plans during the study period and within one month after the last administration of the study drug, and the subjects do not donate sperm or eggs (oocytes, oocytes) for reproductive or assisted reproductive purposes.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women, or women of (WOCBP) with a positive pregnancy test at screening.
  • A history of drug allergies or allergic diseases (such as asthma, urticaria, eczema).
  • Dermatitis, etc., or as determined by the investigator, it may or is clear to be effective against the research drug (including similar drugs and controls) or allergy to the medicine and any of its . Clinically significant underlying liver diseases or medical history, including chronic , chronic , and alcohol liver disease and metabolism-related fatty liver disease, etc.
  • Fever symptom or active infection within one week before the first administration of the drug.
  • (AST) and/or alanine aminotransferase (ALT) and/or the total (TBIL) is higher than the value (ULN) during screening.
  • Have undergone gastric surgery, vagotomy, intestinal resection or any other procedures that might interfere with the gastrointestinal tract surgical procedures for peristalsis, pH or absorption.
  • Have received active or attenuated vaccines within 4 weeks before screening. ·Any of the following drugs or treatments were used before the first administration.
  • Drug or drug abuse, alcohol abuse, smoking addiction or special diet, etc. Any one of the antibody results is positive: Hepatitis B surface antigen, hepatitis C antibody, Treponema pallidum antibody, (HIV).
  • Have participated in clinical studies of other drugs and taken any clinical study drugs within 3 months prior to the screening.
  • Who have donated blood or lost ≥400 mL of blood, received blood transfusion or used blood products within 3 months prior to the screening.
  • There is any disease history or current illness that may affect the safety of the subjects or the in vivo process of the drug, including but not limited to the central nervous system, cardiovascular system, digestive system, respiratory system and endocrine system, urinary system, blood system, immune system, psychiatry, metabolic disorders, and those who have undergone gastrointestinal surgery (Except for cauditis surgery), etc.
  • History of fainting from needles or blood, and it has been judged by the researcher to be of clinical significance.
  • Any other reason, the researcher determines that the subject is not suitable to participate in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    SAD 50mg Fasting

    6 subjects received active drug and 2 subjects received placebo once daily under fasting condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    SAD 150mg Fasting

    6 subjects received active drug and 2 subjects received placebo once daily under fasting condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    SAD 300mg Fasting

    6 subjects received active drug and 2 subjects received placebo once daily under fasting condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    SAD 150mg Fed

    6 subjects received active drug and 2 subjects received placebo once daily under fed condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    SAD 300mg Fed

    6 subjects received active drug and 2 subjects received placebo once daily under fed condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    SAD 600mg Fed

    6 subjects received active drug and 2 subjects received placebo once daily under fed condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    MAD 150mg Fasting

    6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    MAD 150mg Fed

    6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition

    Drug: SAL0133 · Drug: SAL0133 placebo

  • Experimental
    MAD 300mg Fed

    6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition

    Drug: SAL0133 · Drug: SAL0133 placebo

Interventions

  • DrugSAL0133

    once daily single dose or seven days multiple dose of SAL0133 tables

    Also known as: active drug group

  • DrugSAL0133 placebo

    once daily single dose or seven days multiple dose of SAL0133 placebo

    Also known as: placebo group

06

What researchers measure

Primary outcomes

  1. The rate of AE

    The rate of AE occurred in the whole study

    Time frame: from Day 1 to Day 5 or Day 10

  2. The rate of SAE

    The rate of SAE occurred in the whole study

    Time frame: from Day 1 to Day 5 or Day 10

  3. blood pressure

    the change (mmHg) of blood pressure including SBP and DBP in the whole study

    Time frame: from Day 1 to Day 5 or Day 10

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jun 2025, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 22, 2025
StartActual
Jan 10, 2023
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07030504
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jan 10, 2023
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jun 22, 2025

Study contacts

Hongying Yang, M.D
principal investigator · Shenzhen People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion